Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom [Yah...
CymaBay Therapeutics Inc. (CBAY)
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cymabay.com
Company Research
Source: Yahoo! Finance
The global primary biliary cholangitis therapeutics market is anticipated to witness considerable expansion, with expectations to surge from USD 0.742 billion in 2023 to an estimated USD 1.66 billion by 2034. This comprehensive, in-depth analysis highlights the significant growth potential of the primary biliary cholangitis (PBC) therapeutics market. Emerging trends, robust growth, and increasing awareness about PBC treatments contribute significantly to the market's expected Compound Annual Growth Rate (CAGR) of 7.61% during the forecast period of 2024 to 2034. The report sheds light on various crucial aspects poised to influence the market trajectory. Factors such as the escalating global prevalence of primary biliary cholangitis, advancements in therapeutic development, enhanced accessibility to healthcare services, and supportive governmental healthcare policies play a pivotal role in shaping the market's evolution. Analyzed Market Dynamics: A Focus on Treatment Types and D
Show less
Read more
Impact Snapshot
Event Time:
CBAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBAY alerts
High impacting CymaBay Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CBAY
News
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer [Yahoo! Finance]Yahoo! Finance
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
CBAY
Earnings
- 11/7/23 - Miss
CBAY
Sec Filings
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- CBAY's page on the SEC website